Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HSCT vs alemtuzumab, cladribine or ocrelizumab in relapsing remitting multiple sclerosis
2017-001362-25Phase 3Active
- Sponsor
- Helse Bergen
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of autologous hematopoietic stem cells, alemtuzumab, cladribine and ocrelizumab in multiple sclerosis (MS) (4 arms), sponsored by Helse Bergen. Primary endpoint: Primary endpoint (Part I). Started Oct 2017; status: active.
02
Drugs
autologous hematopoietic stem cellsalemtuzumabcladribineocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-001362-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001362-25.